+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Addison's Disease Treatment Market by Drug Class, Diagnosis, Treatments, Distribution Channel, Route of Administration - Global Forecast 2025-2030- Product Image
Addison's Disease Treatment Market by Drug Class, Diagnosis, Treatments, Distribution Channel, Route of Administration - Global Forecast 2025-2030- Product Image
Sale

Addison's Disease Treatment Market by Drug Class, Diagnosis, Treatments, Distribution Channel, Route of Administration - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 195 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5716017
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Addison's Disease Treatment Market grew from USD 1.41 billion in 2023 to USD 1.54 billion in 2024. It is expected to continue growing at a CAGR of 10.72%, reaching USD 2.88 billion by 2030.

Addison's Disease, also known as primary adrenal insufficiency, is a rare endocrine disorder characterized by the inadequate production of hormones, such as cortisol and aldosterone, by the adrenal glands. The scope of the Addison's Disease treatment market includes pharmaceutical therapies like hormone replacement medications such as hydrocortisone, prednisone, and fludrocortisone, which aim to manage symptoms and restore hormone levels. The necessity of these treatments arises from vital needs to prevent life-threatening adrenal crises and improve patients' quality of life. Applications of Addison's Disease treatments are primarily clinical, directed towards disease management and symptom alleviation, impacting end-users such as hospitals, clinics, and individual patients. The market is influenced by factors like advancements in diagnostic technologies, increasing awareness about rare diseases, and rising healthcare expenditures, driving growth by enabling prompt diagnosis and effective management strategies. Opportunities lie in personalized medicine development, aiming at tailored treatment regimens based on genetic or phenotypic markers. Continuing to expand awareness campaigns and enhance access to diagnosis - especially in developing regions - are recommended strategies to seize potential opportunities. However, challenges persist, including the rarity of the condition, which limits extensive market research and the high cost of lifelong treatment, impacting insurance acceptance and affordability. Regulatory hurdles for orphan drug approval and stringent clinical trial requirements further hinder market expansion. Key areas for innovation include the development of non-invasive diagnostics, improved drug formulations with fewer side effects, and innovative delivery systems, such as implants or slow-release injectables. The market is niche yet ripe for targeted research investment, as it remains largely unmet in demand for effective management therapies and curative treatments. The treatment landscape is predominantly driven by pharmaceutical companies focusing on rare disease portfolios, underscoring a lucrative yet challenging nature necessitating dynamic strategic approaches for sustainable growth.

Understanding Market Dynamics in the Addison's Disease Treatment Market

The Addison's Disease Treatment Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising incidences of Addison's disease globally
    • Growing awareness regarding adrenal insufficiency
    • Inception of robust healthcare infrastructure and favorable reimbursement policies
  • Market Restraints
    • High costs associated with the Addison treatment medications
  • Market Opportunities
    • Growing demand for new generation technologically integrated advanced therapeutic drugs
    • Increasing R&D activities and rising focus of the companies in developing treatments for Addison's disease
  • Market Challenges
    • Lack of awareness among people regarding Addison's disease

Exploring Porter’s Five Forces for the Addison's Disease Treatment Market

Porter’s Five Forces framework further strengthens the insights of the Addison's Disease Treatment Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Addison's Disease Treatment Market

External macro-environmental factors deeply influence the performance of the Addison's Disease Treatment Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Addison's Disease Treatment Market

The Addison's Disease Treatment Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Addison's Disease Treatment Market

The Addison's Disease Treatment Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Addison's Disease Treatment Market

The Addison's Disease Treatment Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Addison's Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Actiza Pharmaceutical Private Limited, Akorn Operating Company LLC, Amgen Inc., Amneal Pharmaceuticals, Inc., Bay Biosciences LLC, Bayer AG, Bio-Techne Corporation, Biogen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, BTL Biotechno Labs Pvt Ltd., Cardinal Health, Inc., Eli Lilly and Company, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, LUMITOS AG, Lupin Limited, Merck KGaA, Neurocrine Biosciences, Inc., Novartis AG, Pfizer Inc., Recipharm AB, Sandoz International GmbH, and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Addison's Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Drug Class
    • Glucocorticoid
      • Dexamethasone
      • Hydrocortisone
      • Prednisone
    • Mineralocorticoid
      • Fludrocortisone
  • Diagnosis
    • Imaging Testing
    • Laboratory Testing
  • Treatments
    • Corticosteroid Injections
    • Naturopathic Solutions
    • Oral Corticosteroids
  • Distribution Channel
    • E-Commerce
    • Hospital Pharmacy
    • Retail Pharmacy
  • Route of Administration
    • Oral
    • Parental
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidences of Addison's disease globally
5.1.1.2. Growing awareness regarding adrenal insufficiency
5.1.1.3. Inception of robust healthcare infrastructure and favorable reimbursement policies
5.1.2. Restraints
5.1.2.1. High costs associated with the Addison treatment medications
5.1.3. Opportunities
5.1.3.1. Growing demand for new generation technologically integrated advanced therapeutic drugs
5.1.3.2. Increasing R&D activities and rising focus of the companies in developing treatments for Addison's disease
5.1.4. Challenges
5.1.4.1. Lack of awareness among people regarding Addison's disease
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Addison's Disease Treatment Market, by Drug Class
6.1. Introduction
6.2. Glucocorticoid
6.2.1. Dexamethasone
6.2.2. Hydrocortisone
6.2.3. Prednisone
6.3. Mineralocorticoid
6.3.1. Fludrocortisone
7. Addison's Disease Treatment Market, by Diagnosis
7.1. Introduction
7.2. Imaging Testing
7.3. Laboratory Testing
8. Addison's Disease Treatment Market, by Treatments
8.1. Introduction
8.2. Corticosteroid Injections
8.3. Naturopathic Solutions
8.4. Oral Corticosteroids
9. Addison's Disease Treatment Market, by Distribution Channel
9.1. Introduction
9.2. E-Commerce
9.3. Hospital Pharmacy
9.4. Retail Pharmacy
10. Addison's Disease Treatment Market, by Route of Administration
10.1. Introduction
10.2. Oral
10.3. Parental
11. Americas Addison's Disease Treatment Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Addison's Disease Treatment Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Addison's Disease Treatment Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. ADDISON'S DISEASE TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. ADDISON'S DISEASE TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 13. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 15. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. ADDISON'S DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. ADDISON'S DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ADDISON'S DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ADDISON'S DISEASE TREATMENT MARKET DYNAMICS
TABLE 7. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY HYDROCORTISONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY PREDNISONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY FLUDROCORTISONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY IMAGING TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY NATUROPATHIC SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ORAL CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY PARENTAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. CANADA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 53. CANADA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 54. CANADA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 55. CANADA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 56. CANADA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 57. CANADA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 58. CANADA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. MEXICO ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 60. MEXICO ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 61. MEXICO ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 62. MEXICO ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 63. MEXICO ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 64. MEXICO ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. MEXICO ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 74. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 78. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 79. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 82. AUSTRALIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 83. AUSTRALIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 84. AUSTRALIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 85. AUSTRALIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 86. AUSTRALIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 87. AUSTRALIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. AUSTRALIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. CHINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 90. CHINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 91. CHINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 92. CHINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 93. CHINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 94. CHINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. CHINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. INDIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 97. INDIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 98. INDIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 99. INDIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 100. INDIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 101. INDIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. INDIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. INDONESIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 104. INDONESIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 105. INDONESIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 106. INDONESIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 107. INDONESIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 108. INDONESIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. INDONESIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 110. JAPAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 111. JAPAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 112. JAPAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 113. JAPAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 114. JAPAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 115. JAPAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. JAPAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. MALAYSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 118. MALAYSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 119. MALAYSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 120. MALAYSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 121. MALAYSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 122. MALAYSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 123. MALAYSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. PHILIPPINES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 125. PHILIPPINES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 126. PHILIPPINES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 127. PHILIPPINES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 128. PHILIPPINES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 129. PHILIPPINES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. PHILIPPINES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. SINGAPORE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 132. SINGAPORE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 133. SINGAPORE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 134. SINGAPORE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 135. SINGAPORE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 136. SINGAPORE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. SINGAPORE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. SOUTH KOREA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 139. SOUTH KOREA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 140. SOUTH KOREA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 141. SOUTH KOREA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 142. SOUTH KOREA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 143. SOUTH KOREA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. SOUTH KOREA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. TAIWAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 146. TAIWAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 147. TAIWAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 148. TAIWAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 149. TAIWAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 150. TAIWAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 151. TAIWAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 152. THAILAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 153. THAILAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 154. THAILAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 155. THAILAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 156. THAILAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 157. THAILAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. THAILAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 159. VIETNAM ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 160. VIETNAM ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 161. VIETNAM ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 162. VIETNAM ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 163. VIETNAM ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 164. VIETNAM ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. VIETNAM ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 174. DENMARK ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 175. DENMARK ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 176. DENMARK ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 177. DENMARK ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 178. DENMARK ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 179. DENMARK ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. DENMARK ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. EGYPT ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 182. EGYPT ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 183. EGYPT ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 184. EGYPT ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 185. EGYPT ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 186. EGYPT ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. EGYPT ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. FINLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 189. FINLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 190. FINLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 191. FINLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 192. FINLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 193. FINLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. FINLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 195. FRANCE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 196. FRANCE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 197. FRANCE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 198. FRANCE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 199. FRANCE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 200. FRANCE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. FRANCE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 202. GERMANY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 203. GERMANY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 204. GERMANY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 205. GERMANY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 206. GERMANY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 207. GERMANY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. GERMANY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. ISRAEL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 210. ISRAEL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 211. ISRAEL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 212. ISRAEL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 213. ISRAEL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 214. ISRAEL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 215. ISRAEL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 216. ITALY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 217. ITALY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 218. ITALY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 219. ITALY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 220. ITALY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 221. ITALY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. ITALY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 227. NETHERLANDS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 228. NETHERLANDS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. NETHERLANDS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. NIGERIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 231. NIGERIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 232. NIGERIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 233. NIGERIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 234. NIGERIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 237. NORWAY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 238. NORWAY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 239. NORWAY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 240. NORWAY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 241. NORWAY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 242. NORWAY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 243. NORWAY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. POLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 245. POLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 246. POLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 247. POLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 248. POLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 249. POLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 250. POLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 251. QATAR ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 252. QATAR ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 253. QATAR ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 254. QATAR ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 255. QATAR ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 256. QATAR ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. QATAR ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 258. RUSSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 259. RUSSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 260. RUSSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 261. RUSSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 262. RUSSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 263. RUSSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 264. RUSSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 266. SAUDI ARABIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 268. SAUDI ARABIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 270. SAUDI ARABIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 272. SOUTH AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 273. SOUTH AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 274. SOUTH AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 276. SOUTH AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 278. SOUTH AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 279. SPAIN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 280. SPAIN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 281. SPAIN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 282. SPAIN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 283. SPAIN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 284. SPAIN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 285. SPAIN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 286. SWEDEN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 287. SWEDEN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 288. SWEDEN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 289. SWEDEN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 290. SWEDEN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 291. SWEDEN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 292. SWEDEN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 293. SWITZERLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 294. SWITZERLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 295. SWITZERLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 296. SWITZERLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 297. SWITZERLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 298. SWITZERLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 299. SWITZERLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 300. TURKEY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 301. TURKEY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 302. TURKEY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 303. TURKEY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 304. TURKEY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 305. TURKEY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 306. TURKEY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 307. UNITED ARAB EMIRATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 308. UNITED ARAB EMIRATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
TABLE 309. UNITED ARAB EMIRATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
TABLE 310. UNITED ARAB EMIRATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 311. UNITED ARAB EMIRATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 312. UNITED ARAB EMIRATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 313. UNITED ARAB EMIRATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 314. UNITED KINGDOM

Companies Mentioned

The leading players in the Addison's Disease Treatment Market, which are profiled in this report, include:
  • Abbott Laboratories
  • Actiza Pharmaceutical Private Limited
  • Akorn Operating Company LLC
  • Amgen Inc.
  • Amneal Pharmaceuticals, Inc.
  • Bay Biosciences LLC
  • Bayer AG
  • Bio-Techne Corporation
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • BTL Biotechno Labs Pvt Ltd.
  • Cardinal Health, Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • LUMITOS AG
  • Lupin Limited
  • Merck KGaA
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Recipharm AB
  • Sandoz International GmbH
  • Takeda Pharmaceutical Company Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages195
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 1.54 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.88 Billion
Compound Annual Growth Rate10.7%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Addison's Disease Testing Market by Offering, Test Type, Sample Type, End-Use - Global Forecast 2025-2030 - Product Image

Addison's Disease Testing Market by Offering, Test Type, Sample Type, End-Use - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Addison's Disease - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Addison's Disease - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Addisons Disease Therapeutics Market 2024-2028 - Product Image

Addisons Disease Therapeutics Market 2024-2028

  • Report
  • 166 Pages
  • Global
From
Thyroid Eye Disease Treatments Market by Drug, Route of Administration, Treatment, Diagnosis, Distribution - Global Forecast 2025-2030 - Product Image

Thyroid Eye Disease Treatments Market by Drug, Route of Administration, Treatment, Diagnosis, Distribution - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Congenital Adrenal Hyperplasia Market Insight, Epidemiology And Market Forecast - 2034 - Product Image

Congenital Adrenal Hyperplasia Market Insight, Epidemiology And Market Forecast - 2034

  • Report
  • 138 Pages
  • Global
From

About the Addisons Disease Drug Market

Addisons Disease Drug market is a segment of the Endocrine and Metabolic Disorders Drugs market. It is a specialized market that focuses on drugs used to treat Addisons Disease, a rare disorder of the adrenal glands. These drugs are used to replace the hormones that the adrenal glands are not producing, and to help regulate the body's metabolism. The drugs are typically administered orally or through injections, and may be used in combination with other treatments. The Addisons Disease Drug market is a small but growing market, with a focus on providing effective treatments for this rare disorder. Companies in the market are researching and developing new drugs to improve the quality of life for those suffering from Addisons Disease. Some companies in the Addisons Disease Drug market include Novartis, Pfizer, Merck, and AbbVie. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.